Ionis Pharmaceuticals Inc reported results for the quarter ended 2026 with revenue of $267.95M, a net loss of ($114.65M) and diluted loss per share of ($0.69), compared with revenue of $452.05M, net income of $123.55M and EPS of $0.7 in the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$267.95M$452.05M(40.7%) | Net income²($114.65M)$123.55M(192.8%) | Diluted EPS³($0.69)$0.7(198.6%) |
¹ Reported as “Total revenue”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted net income (loss) per share”.
Business Highlights
- Revenue mix shifted as R&D revenue declined year over year with the lapse of 2025 upfront licensing payments, while commercial revenue rose, driven by DAWNZERA and other product sales.
- Commercial momentum continued with independent U.S. launches of TRYNGOLZA and DAWNZERA; the company is preparing an independent launch of zilganersen in AxD pending approval.
- Portfolio expansion includes seven marketed medicines and multiple Phase 3 programs, supporting expected growth in product and royalty streams.
- SG&A and commercialization costs increased to support launches; headcount grew to 1,480 as the company scales independent commercialization.
- Ongoing collaborations include cost-share and joint development with AstraZeneca for WAINUA and milestone/license revenue from partners such as the sapablursen transaction with Ono.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.